Replies to post #177059 on Biotech Values

[genisi]

I don’t recall MNTA’s having cited any external “experts” to support its contention that generic Copaxone is approvable under the 505(j) pathway.

Perhaps Momenta has more confidence in its internal experts, but that's a different issue. I doubt that Teva’s corporate culture would change much, it's very much imprinted.